CD274 and neoplasm: The first results of the safety analysis of 43 PD-L1-positive (CPS ≥ 1), non-MSI patients treated with margetuximab plus retifanlimab (cohort A) were presented at ESMO 2021, reporting a tumor shrinkage of 85.7% (30/35 patients).